Danish Commercial Services Stock News

CPSE:GMAB
CPSE:GMABBiotechs

Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Swings And Cooling Near Term Momentum

Genmab (CPSE:GMAB) is back on investors’ radar after recent share price swings, with the stock showing a 0.3% move over the past day but negative returns over the past month and past 3 months. See our latest analysis for Genmab. That recent 7 day share price return of 7.6% decline and 30 day share price return of 11.2% decline sit against a 1 year total shareholder return of 41.2%. This suggests near term momentum has cooled after a strong longer term run. If Genmab’s moves have you thinking...
CPSE:GN
CPSE:GNConsumer Durables

GN Store Nord (CPSE:GN) Valuation After Weaker Full Year Earnings And Softer Growth

GN Store Nord (CPSE:GN) has drawn fresh attention after reporting full year 2025 earnings, with sales of DKK 16,782 million and net income of DKK 653 million, both lower than the previous year. See our latest analysis for GN Store Nord. The latest full year earnings release appears to have weighed on sentiment, with the share price at DKK98.7 after a 7 day share price return of 8.14% and a 30 day share price return of 11.91%. However, the 1 year total shareholder return of 30.91% and 5 year...
CPSE:NKT
CPSE:NKTElectrical

A Look At NKT (CPSE:NKT) Valuation After Its Long Term Mainova Power Grid Partnership

NKT (CPSE:NKT) is back in focus after agreeing an exclusive long-term partnership with German grid operator Mainova, securing a cable supply role in Frankfurt’s power grid upgrade through 2033. See our latest analysis for NKT. Those headlines around Frankfurt’s grid upgrade and the new power purchase agreement with Uniper come on top of a 90 day share price return of 16.67% and a 1 year total shareholder return of 75.15%, signalling momentum that investors are watching closely beyond the...
CPSE:VWS
CPSE:VWSElectrical

A Look At Vestas Wind Systems (CPSE:VWS) Valuation After 2025 Results Guidance Dividend And New Order

Vestas Wind Systems (CPSE:VWS) just reported its fourth quarter and full year 2025 results, released new 2026 guidance, and paired that with a proposed dividend, a completed buyback, and fresh order intake. See our latest analysis for Vestas Wind Systems. The earnings release, fresh 2026 guidance, completed buyback and new Kapuni order come after a weak 7 day share price return of 16.55% decline and a year to date share price return of 7.86% decline. However, the 1 year total shareholder...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Is Coloplast (CPSE:COLO B) Prioritising EBIT Growth Over Top-Line Momentum In Its Latest Results?

In early February 2026, Coloplast A/S reported first-quarter 2025-2026 results showing sales of DKK 7,043 million and net income of DKK 1,397 million, alongside updated guidance for around 7% EBIT growth in constant currencies for the fiscal year. The combination of modest sales movement but higher earnings per share suggests improved profitability, which can influence how investors assess Coloplast’s operational efficiency and earnings quality. Next, we’ll examine how Coloplast’s focus on...
CPSE:AMBU B
CPSE:AMBU BMedical Equipment

February 2026's European Stocks Estimated To Be Below Fair Market Value

As European markets remain buoyant, with the STOXX Europe 600 Index reaching new highs and optimism about the eurozone economy prevailing, investors are keenly observing potential opportunities amid recent market volatility. In this context, identifying stocks that may be undervalued relative to their intrinsic worth can be a strategic approach for those looking to capitalize on market conditions where cyclical and value-oriented segments are gaining traction.
CPSE:SPKSJF
CPSE:SPKSJFBanks

Discovering Europe's Hidden Stock Gems In February 2026

As the pan-European STOXX Europe 600 Index reaches new highs, optimism about the eurozone economy is helping to counterbalance recent market volatility. With inflation slowing faster than forecast and key interest rates remaining steady, investors are increasingly focusing on small-cap stocks that may offer unique opportunities in this evolving landscape. Identifying promising stocks often involves looking for companies with strong fundamentals and potential growth catalysts that align well...
CPSE:TRYG
CPSE:TRYGInsurance

Assessing Tryg (CPSE:TRYG) Valuation After Announcing A DKK 1.0b Share Buyback Programme

Tryg (CPSE:TRYG) has drawn fresh attention after its Board approved a share buyback programme of up to DKK 1.0b, running until 13 May 2026, with treasury holdings now at 11,308,326 shares. See our latest analysis for Tryg. At a share price of DKK155.0, Tryg has had a softer patch recently, with a 30 day share price return of 2.64% decline and a year to date share price return of 6.12% decline, even as the 1 year total shareholder return sits at 9.82%. This suggests longer term holders have...
CPSE:RILBA
CPSE:RILBABanks

A Look At Ringkjøbing Landbobank (CPSE:RILBA) Valuation After New 40% Payout Policy And Capital Changes

Ringkjøbing Landbobank (CPSE:RILBA) has given investors a lot to digest by combining its full year 2025 results, a new 40% profit distribution policy and proposed changes to its capital authorisations and share capital. See our latest analysis for Ringkjøbing Landbobank. These announcements land after a strong run in the share price, with a 30 day share price return of 9.99% and a 1 year total shareholder return of 51.35%. This suggests positive momentum has been building around Ringkjøbing...
CPSE:VWS
CPSE:VWSElectrical

Vestas Order At Kapuni Links Wind Turbines To Green Hydrogen Growth

Vestas Wind Systems (CPSE:VWS) has secured an order for the Kapuni Wind Farm in New Zealand. The project is one of New Zealand's first large-scale efforts to pair wind power with green hydrogen production. Kapuni is intended to support New Zealand's broader decarbonisation and renewable energy objectives. Kapuni adds another reference project to Vestas' core business in wind turbines and related services, while also highlighting its role in early green hydrogen projects. For you as an...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Coloplast (CPSE:COLO B) Margin Compression Challenges Premium Profitability Narrative In Q1 2026

Coloplast Q1 2026 Earnings Snapshot Coloplast (CPSE:COLO B) opened its 2026 financial year with Q1 revenue of DKK 7.0b and basic EPS of DKK 6.21, alongside trailing twelve month EPS of DKK 17.70 and net income of DKK 4.0b. Over recent quarters the company has seen quarterly revenue move in a tight band between DKK 6.9b and DKK 7.0b, while quarterly EPS has ranged from DKK 3.57 to DKK 6.21 as net income shifted between DKK 805m and DKK 1.40b. This sets up this report as a check-in on how much...
CPSE:ORSTED
CPSE:ORSTEDRenewable Energy

Ørsted (CPSE:ORSTED) Returns To Profitability As High P/E Tests Bullish Narratives

Ørsted (CPSE:ORSTED) closed out FY 2025 with Q4 revenue of DKK23.1b and a basic EPS loss of DKK1.77, while trailing twelve month EPS sat at DKK1.95 on revenue of DKK73.2b. Over recent periods the company has seen quarterly revenue range from DKK12.3b to DKK23.1b and EPS swing from a profit of DKK10.57 in Q1 2025 to losses in Q3 and Q4. Investors are watching how consistently that full year profitability holds up. With trailing net income of DKK1.7b against those sizable top line figures, the...